Immuron Ltd has released a press release.
IMM-529 pre-IND FDA filing
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Immuron
- Immuron Travelan sales continued strong growth
- Travelan to progress to Phase 3 Clinical Trials in the US
- Immuron achieves record Travelan sales
- Immuron achieves record half yearly Travelan sales
- First Patients Enrolled in Campylobacter Clinical Study
Later from Immuron
- Immuron Travelan record sales globally, Australia and USA
- Appendix 4E and Preliminary Final Report
- Immuron Plans Phase 2 Trial for IMM-529 following FDA review
- Trading Halt
- NMRC Reports Results for Campylobacter Clinical Study
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron